BBC Homepage World Service Education
BBC Homepagelow graphics version | feedback | help
BBC News Online
 You are in: Health
Front Page 
World 
UK 
UK Politics 
Business 
Sci/Tech 
Health 
Background Briefings 
Medical notes 
Education 
Entertainment 
Talking Point 
In Depth 
AudioVideo 


The BBC's James Westhead
"It is not a magic solution"
 real 28k

Dr Mark Britton, British Lung Foundation
Describes how Zyban works
 real 28k

Tuesday, 27 June, 2000, 07:28 GMT 08:28 UK
Smoking 'wonder' drug hits UK
Zyban
Zyban has produced good results in trials
A drug that can help smokers to quit the habit is launched in the UK on Tuesday.

The NHS has agreed to pay for the drug, Zyban, which is being hailed as a major breakthrough in helping smokers to beat their addiction.

The pill acts on the brain to quash the craving for nicotine that tobacco products produce.

It is the first anti-smoking medication licensed in the UK that does not contain nicotine itself.

Every hour 13 people die in the UK from smoking-related diseases - a quarter of these in middle age.

A survey has shown that more than two-thirds of smokers (68%) want to give up.

However, studies show that only 3% will be able to do so using willpower alone because their bodies are addicted to nicotine. This craving can be as powerful as addiction to class A drugs such as heroin or cocaine.

There are a range of products available to help people quit smoking.

But they rely on giving the body a shot of nicotine to replace that provided by tobacco products.

Nicotine rush


Possible side effects
dry mouth
headache
insomnia
Zyban should not be prescribed for patients with a history of epilepsy or seizures

Within 10 seconds of inhaling from a cigarette, a concentrated dose of nicotine is delivered directly to the brain.

This 'rush' stimulates the release of a number of naturally occurring neurotransmitters in the brain.

Over time the effects on these neurotransmitters - particularly dopamine and noradrenaline - cause a smoker to become physically addicted to nicotine.

When smokers quit, neurotransmitter levels are altered causing cravings, anxiety and irritability.

Zyban acts on the addiction process by helping to put these levels back to normal.

A study published in the New England Journal of Medicine found that almost one in three people (30.3%) treated with Zyban were not smoking at one year.

In this study, Zyban was found to be almost twice as effective as a nicotine patch in helping people to quit smoking and to stay off tobacco for at least one year.

Biochemical basis

Dr Chris Steele, a Manchester GP and expert on smoking, said: "Most smokers do not continue to smoke cigarettes out of habit, but because they are addicted to nicotine.

"Zyban is the first non-nicotine prescription medication that tackles the biochemical basis of nicotine addiction."



Zyban is good, but it is not a silver bullet

Clive Bates, Action on Smoking and Health

Health Secretary Alan Milburn said the treatment, which will cost the NHS 42.85 per month for each patient prescribed the drug, was "good news for the 70% of smokers who say they want to give up".

He added: "We have already invested 30 million over two years on setting up specialist smoking cessation services in the NHS and this announcement is another step towards ensuring that our health service leads the world in its smoking cessation services."

Clive Bates, director of the anti-smoking charity Action on Smoking and Health (ASH) disputed the figures from the Zyban study and said other treatments were also effective.

However, he said: "The launch of Zyban is good news for smokers.

"This is a significant development because it means that smoking cessation treatment will become a mainstream part of the NHS. Doctor will now have a tool with which they can help people to give up smoking."

However, he added: "Zyban is good, but it is not a silver bullet - smokers are still going to need lots willpower and determination to keep trying."

Dr Mark Britton, chairman of the British Lung Foundation, said: "Zyban is the first new innovation to help smokers kick the habit that we've seen in almost a decade.

"We welcome this exciting advance to help smokers break their addiction."

Smoking costs 1.7billion to the NHS every year in terms of GP consultations, prescriptions and hospital care.

Zyban available in tablet form on prescription and is taken as a two-month course.

Developed by Glaxo Wellcome, Zyban has already been licensed in the US, Canada and Holland.

Search BBC News Online

Advanced search options
Launch console
BBC RADIO NEWS
BBC ONE TV NEWS
WORLD NEWS SUMMARY
PROGRAMMES GUIDE
Internet links:


The BBC is not responsible for the content of external internet sites

Links to more Health stories are at the foot of the page.


E-mail this story to a friend

Links to more Health stories